Ann: Quarterly Update and Appendix 4C, page-11

Dr Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said:“Creso Pharma is performing very well. In Quarter 4 of 2019, Creso Pharma’s total unaudited revenues were AUD 1.986 million. For the full year 2019 unaudited revenues were AUD 3.651 million showing strong growth in market acceptance for Creso Pharma products and successful penetration of new markets. In addition, the Company made considerable progress with the development and expansion of its product portfolio.Creso Pharma has an expanding portfolio of innovative products and a leadership team with vast experience in the pharmaceutical industry. The Company’s products are now sold across Europeand Oceania, and will soon be available inSouth Africa. We are confident in our ability to successfully commercialise our new and existing products, and we look forward to updating shareholders on our continuing progress and growth.”